Novo Nordisk's CagriSema achieved 20.7% and 21.0% weight loss at 68 weeks in REDEFINE 9 trial
NVO•In the REDEFINE 9 trial, CagriSema doses of 1.7 mg/1.7 mg and 1.0 mg/1.0 mg achieved average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, versus 2.0% with placebo.
